SABSW · As filed with the SEC
SAB Biotherapeutics balance sheet, by fiscal year
The statement as SAB Biotherapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash and cash equivalents | 10,502,680 | 8,897,966 | 56,566,066 | 15,046,894 |
| Restricted cash | — | — | — | 0 |
| Short-term investments | 86,089,779 | 11,862,746 | — | — |
| Accounts receivable, net | — | — | 0 | 5,556,577 |
| Prepaid expenses | — | — | — | 1,493,982 |
| Accrued interest receivable | 946,781 | 54,955 | — | — |
| Prepaid expenses and other current assets | 3,513,384 | 2,976,562 | 2,340,797 | — |
| Total current assets | 101,052,624 | 23,792,229 | 58,906,863 | 22,097,453 |
| Deferred issuance cost | 150,145 | 261,105 | — | — |
| Long-term prepaid assets | 5,309,345 | 220,997 | 350,230 | 467,694 |
| Long-term investments | 46,892,882 | — | — | — |
| Operating lease right-of-use assets | 2,603,059 | 970,294 | 1,277,982 | 1,192,054 |
| Financing lease right-of-use assets | 3,496,012 | 3,582,835 | 3,669,659 | 3,896,873 |
| Property, plant and equipment, net | 13,305,902 | 15,368,009 | 19,736,519 | 23,250,853 |
| Total assets | 172,809,969 | 44,195,469 | 83,941,253 | 50,904,927 |
| Liabilities and Stockholders Equity | ||||
| Current liabilities | ||||
| Accounts payable | 3,145,805 | 1,694,722 | 945,927 | 3,679,116 |
| Forward share purchase liability | — | — | — | 0 |
| Notes payable | 0 | 275,849 | 1,050,849 | 772,665 |
| Accrued expenses and other current liabilities | 6,583,996 | 5,473,036 | 6,692,181 | 9,917,981 |
| Operating lease liabilities, current portion | 797,402 | 393,430 | 669,946 | 490,794 |
| Finance lease liabilities, current portion | 153,967 | 142,563 | 132,004 | 132,788 |
| Due to related party | — | — | — | 0 |
| Deferred grant income | — | 0 | 1,322,410 | 0 |
| Total current liabilities | 10,681,170 | 7,979,600 | 10,813,317 | 14,993,344 |
| Operating lease liabilities, noncurrent | 1,877,360 | 581,148 | 635,777 | 361,225 |
| Finance lease liabilities, noncurrent | 3,121,952 | 3,275,919 | 3,418,483 | 3,629,642 |
| Warrant liabilities | 5,635,112 | 6,389,226 | 11,774,235 | 320,930 |
| Convertible Debt | — | — | — | 541,644 |
| Notes payable, noncurrent | — | — | 0 | — |
| Total liabilities | 21,315,594 | 18,225,893 | 26,641,812 | 19,846,785 |
| Stockholders' equity | ||||
| Preferred stock | — | 5 | 5 | 0 |
| Preferred Series A | 3 | — | — | — |
| Preferred Series B | 64 | — | — | — |
| Common stock; $0.0001 par value; 800,000,000 shares authorized at December 31, 2025 and December 31, 2024; 47,664,564 and 9,343,533 shares issued at December 31, 2025 and December 31, 2024, respectively, and 47,609,899 and 9,288,868 outstanding at December 31, 2025 and December 31, 2024, respectively | 4,766 | 935 | 929 | 5,094 |
| Treasury stock, at cost; 54,665 shares held at December 31, 2025 and December 31, 2024, respectively | (5,521,246) | (5,521,246) | (5,521,246) | (5,521,246) |
| Additional paid-in capital | 267,719,445 | 155,794,142 | 152,856,874 | 84,444,049 |
| Accumulated other comprehensive income (loss) | 186,510 | (135,410) | 26,420 | — |
| Accumulated deficit | (110,895,167) | (124,168,850) | (90,063,541) | (47,869,755) |
| Total stockholders' equity | 151,494,375 | 25,969,576 | 57,299,441 | 31,058,142 |
| Total liabilities and stockholders' equity | 172,809,969 | 44,195,469 | 83,941,253 | 50,904,927 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.